Neurofibromatoses type I is a genetic condition characterized by the growth of tumours along the nerves in the brain, skin and other parts of the body, and skin pigmentation. Neurofibromatoses is an autosomal dominant disorder which is caused by the mutation in NF1 gene, a tumour suppressor gene, that encodes protein to stop growing and dividing in an uncontrolled manner. The condition usually begins in early childhood, which causes flat patches on the skin that are darker. In later childhood, freckles can be developed in the underarms and groins. The signs and symptoms of neurofibromatoses type I include hypertension, macrocephaly, short stature, skeletal abnormalities, autism spectrum disorder, learning disabilities, and seizures. Universitaire Ziekenhuizen Leuven is in the process of developing lamotrigine as a sodium channel antagonist for the treatment of neurofibromatoses type I. University of Utah is in the process of developing cholecalciferol for the treatment of neurofibromatoses type I. Some of the companies and universities having the pipeline of neurofibromatoses include Universitaire Ziekenhuizen Leuven, Vanderbilt University, and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.